Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

Real-time Quote. Real-time Tradegate - 09/26 12:38:28 pm
96.085 EUR   -1.84%
09/22 MERCK : and the Royal Health Awareness Society Partner to Advance Wo..
09/21 MERCK : Invests over € 50 million in Flagship Pharmaceutical Packagi..
09/21 GLOBAL AZO PIGM : Basf, Clariant, Lanxess, Eckart, EMD, Merck KGaA, ..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Merck KGaA May Withdraw Research from Portugal over Debt-Report

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/09/2012 | 08:28am CEST

German chemical company Merck KGaA (>> Merck KGaA) may withdraw future investments for research projects in Portugal worth tens of millions of euros unless the government hospitals stick to the agreed-upon debt repayments, German daily newspaper Financial Times Deutschland reports Monday.

Merck Portugal's manager Fritz Sacher told the paper the company's research projects are long-term and require mutual trust as a basis. "The Portuguese government's lacking payment habits undermine this trust," he is quoted as saying.

Portuguese government hospitals owe the pharmaceutical industry a total of more than 1.5 billion euros ($1.84 billion) and companies have to wait nearly 550 days on average until invoices are paid, FTD reports.

Some companies, including Roche Holding AG (ROG.VX), have already halted the sale of medications on credit to highly indebted countries like Portugal, Greece, Spain and Italy until outstanding debts are paid, the paper notes, but for many companies such drastic steps are difficult as they carry responsibility for people's wellbeing.

Withdrawing research projects is a way of putting pressure on the government, as Portugal is an attractive location for research investments, FTD says. "The conditions for certain research and human studies are as good as in the U.S., but it's significantly more cost-effective in Portugal," Sacher told the paper.

Newspaper website: http://www.ftd.de

Write to the Frankfurt Bureau at djnews.frankfurt@dowjones.com

Stocks mentioned in the article : Merck KGaA
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
09/22 MERCK : and the Royal Health Awareness Society Partner to Advance Women's Health..
09/21 MERCK : Invests over € 50 million in Flagship Pharmaceutical Packaging Building ..
09/21 GLOBAL AZO PIGMENTS MARKET 2016 : Basf, Clariant, Lanxess, Eckart, EMD, Merck KG..
09/21 MERCK : Angola Receives 4 Million Praziquantel Tablets
09/20 MERCK : Prexton successfully completes phase 1 Parkinson's disease trial
09/19 MERCK : New Steritest™ Symbio Pump Accessories Enable Faster, Safer Steril..
09/16 MERCK : Presents New Data Examining Durable Efficacy with Investigational Cladri..
09/15 MERCK : Announces 2016 Recipients of € 1 Million Grant for Multiple Sclerosis In..
09/15 MERCK : Findings from Merck KGaA Broaden Understanding of Granular Matter Resear..
09/15 MERCK : "From Glitter to Glamour" – The Merck Pigment Innovation Ronastar®..
More news
Sector news : Specialty & Advanced Pharmaceuticals
07:49aDJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/23 Endo International CEO steps down, Campanelli named successor
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
08/19 ALPHA FROM EQUAL-WEIGHTING : A Look At Materials
08/10 Bristol's Opdivo Fall-Out Brings Others Into Play
08/05 Merck KGaA's (MKGAF) CEO Stefan Oschmann on Q2 2016 Results - Earnings Call T..
08/04 Merck KGaA reports Q2 results
07/18 Merck's marketing application for Cladribine tablets accepted for review in E..
Advertisement
Financials (€)
Sales 2016 15 041 M
EBIT 2016 3 285 M
Net income 2016 1 546 M
Debt 2016 10 800 M
Yield 2016 1,25%
P/E ratio 2016 25,90
P/E ratio 2017 22,47
EV / Sales 2016 1,56x
EV / Sales 2017 1,39x
Capitalization 12 635 M
More Financials
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 104 €
Spread / Average Target 6,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stefan Oschmann Chief Executive Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA9.29%14 203
ABBVIE INC9.69%105 823
BIOGEN INC2.03%68 493
KYOWA HAKKO KIRIN CO L..-14.44%9 295
MALLINCKRODT PLC2.25%8 220
JAZZ PHARMACEUTICALS P..-9.51%7 699
More Results